CA2238875A1 - Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv - Google Patents

Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Info

Publication number
CA2238875A1
CA2238875A1 CA002238875A CA2238875A CA2238875A1 CA 2238875 A1 CA2238875 A1 CA 2238875A1 CA 002238875 A CA002238875 A CA 002238875A CA 2238875 A CA2238875 A CA 2238875A CA 2238875 A1 CA2238875 A1 CA 2238875A1
Authority
CA
Canada
Prior art keywords
pde
tri
inhibitors
ethane derivatives
aryl ethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002238875A
Other languages
English (en)
Other versions
CA2238875C (fr
Inventor
Daniel Guay
Yves Girard
Yves Ducharme
Marc Blouin
Pierre Hamel
Mario Girard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Inc.
Daniel Guay
Yves Girard
Yves Ducharme
Marc Blouin
Pierre Hamel
Mario Girard
Merck Frosst Canada Incorporated
Merck Frosst Canada & Co./Merck Frosst Canada & Cie
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606377.1A external-priority patent/GB9606377D0/en
Application filed by Merck Frosst Canada Inc., Daniel Guay, Yves Girard, Yves Ducharme, Marc Blouin, Pierre Hamel, Mario Girard, Merck Frosst Canada Incorporated, Merck Frosst Canada & Co./Merck Frosst Canada & Cie, Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Inc.
Publication of CA2238875A1 publication Critical patent/CA2238875A1/fr
Application granted granted Critical
Publication of CA2238875C publication Critical patent/CA2238875C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002238875A 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv Expired - Fee Related CA2238875C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US870495P 1995-12-15 1995-12-15
US60/008,704 1995-12-15
GB9606377.1 1996-03-26
GBGB9606377.1A GB9606377D0 (en) 1996-03-26 1996-03-26 Tri-aryl ethane derivatives as PDE IV inhibitors
PCT/CA1996/000839 WO1997022586A1 (fr) 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Publications (2)

Publication Number Publication Date
CA2238875A1 true CA2238875A1 (fr) 1997-06-26
CA2238875C CA2238875C (fr) 2003-09-16

Family

ID=26308993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238875A Expired - Fee Related CA2238875C (fr) 1995-12-15 1996-12-11 Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv

Country Status (5)

Country Link
EP (1) EP0873311A1 (fr)
JP (1) JP3465825B2 (fr)
AU (1) AU707574B2 (fr)
CA (1) CA2238875C (fr)
WO (1) WO1997022586A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
CN1173950C (zh) * 1998-10-06 2004-11-03 大日本制药株式会社 2,3-二取代的吡啶衍生物、其制备方法、含有其的药物组合物和用于制备中的中间体
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
KR100701904B1 (ko) 1999-08-21 2007-04-02 알타나 파마 아게 Ｐｄｅ 억제제 및 베타 2 아드레날린수용체 작동제의상승적 조합
WO2002045718A1 (fr) * 2000-12-08 2002-06-13 Institut Pasteur De Lille Utilisation de composes actifs capables de moduler la voie intracellulaire declenchee par le recepteur de dp dans des cellules de langerhans
CN1520313A (zh) 2001-05-23 2004-08-11 ������ҩ��ʽ���� 一种加速骨折愈合的组合物
CA2447618A1 (fr) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Composition pour le traitement regeneratif de la maladie du cartilage
CA2506297A1 (fr) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Inhibiteurs de la phosphodiesterase 4
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2017173274A1 (fr) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
PE20191147A1 (es) 2016-09-30 2019-09-02 Vertex Pharma Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
UY37513A (es) 2016-12-09 2018-07-31 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
BR112019025801A2 (pt) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
EP3654969A1 (fr) 2017-07-17 2020-05-27 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
AU2018309043B2 (en) 2017-08-02 2022-03-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
WO2019079760A1 (fr) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Formes cristallines et compositions de modulateurs de cftr
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (fr) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation

Also Published As

Publication number Publication date
WO1997022586A1 (fr) 1997-06-26
AU1028097A (en) 1997-07-14
JP2000501742A (ja) 2000-02-15
EP0873311A1 (fr) 1998-10-28
CA2238875C (fr) 2003-09-16
JP3465825B2 (ja) 2003-11-10
AU707574B2 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
CA2238875A1 (fr) Derives d'ethane tri-aryle utilises comme inhibiteurs de pde iv
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
MY132642A (en) Naphthyridine derivatives
WO2005037825A3 (fr) Inhibiteurs de la proteine kinase
EP1070710A3 (fr) Dérivés de dithiolane, leur préparation et leur action thérapeutique
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
WO2001087882A3 (fr) Derives de pyrrolopyridinone substitues utiles en tant qu'inhibiteurs de la phosphodiesterase
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
CA2414018A1 (fr) Derives de 2-aminocarbonyl-9h-purine
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
WO2004026863A8 (fr) Nouveaux composes de triazole et d'oxazole, inhibiteurs du facteur de croissance transformant
WO2000064874A3 (fr) DERIVES DE PYRIDINE HETEROSUBSTITUES INHIBITEURS DE $i(PDE 4)
WO2003048164A3 (fr) Antagonistes du recepteur a2a de l'adenosine
WO2004026306A3 (fr) Nouveaux composes de pyrazole utilises comme inhibiteurs du facteur de croissance transformant (tgf)
DE60005501D1 (de) 4'-c-ethynyl-pyrimidine nukleoside
WO2004100865A3 (fr) Nouveaux derives de benzimidazole
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
AU5764496A (en) Cyclohexyl dihydrobenzofuranes
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
ATE237614T1 (de) Benzo(c)chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
DE69330601D1 (de) Serotoninergische ergolin derivate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed